Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 116 (5), 1029-1034
- https://doi.org/10.1016/s0016-5085(99)70005-3
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- RESOLUTION OF MUCOSAL INFLAMMATION AND FALL IN IL-1 BETA mRNA IN ACTIVE CROHN'S DISEASE IN RESPONSE TO POLYMERIC DIET CT3211.Journal of Pediatric Gastroenterology and Nutrition, 1997
- An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's diseaseGastroenterology, 1995
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Polgmeric nutrition as the primary therapy in children with small bowel Crohn's diseaseAlimentary Pharmacology & Therapeutics, 1994
- Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.Journal of Clinical Investigation, 1994
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut, 1993
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980
- A controlled trial of azathioprine in Crohn's diseaseDigestive Diseases and Sciences, 1975